Nanoparticle-Based Antigen Delivery: Advancing Immunization Strategies against Infectious Pathogens
Open Access
- 1 January 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Biomaterials Research
- Vol. 30
Abstract
Stimulation of adaptive immunity is a goal to defend against infectious agents. In recent years, vaccine development and improvements in their efficacy have been thoroughly investigated, and highly effective vaccines have been released to the market. The administration of vaccinations, safety, and the development of immunogenicity pose considerable challenges in this area. Investigations have been conducted on nanoparticle (NP)-based vaccines to address the issue. NPs are used in vaccine development to enhance antigen delivery, provide protection, and serve as adjuvants. The application of nanotechnology has substantially improved the delivery and effectiveness of vaccines by manipulating NP properties. Studies on NP-based immunizations have focused on viral pathogens and bacterial agents. Immunizations utilizing NPs enhance immune responses and stabilize viral antigens, facilitating the development of vaccines for hepatitis B, influenza, and HIV. Nanovaccines specifically target antigens associated with viruses, bacteria, and certain cancers. NP-based vaccines effectively stimulate and mature dendritic cells (DCs) in vitro and in vivo. Following vaccination, the NP-based vaccine resulted in increased cytokine levels and activated Th1 and Th2 cells in vivo. As a result, NP-based vaccines stimulate T-cell immune responses and adaptive immunity driven by immunoglobulin G and immunoglobulin M. This review has discussed the various NPs and antigens used in nanovaccine preparation; the role NPs play in activating adaptive immunity; and, specifically, the maturation of DCs; the activation of Th1 and Th2 cells against viruses, bacteria, and other microbial pathogens; and the safety of NPs.Keywords
This publication has 198 references indexed in Scilit:
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 VaccineJAMA, 2021
- Life-Threatening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of ImmunityJournal of Clinical Immunology, 2019
- Nanovaccine: A novel approach in immunizationJournal of Cellular Physiology, 2019
- Intranasal Nanovaccine Confers Homo‐ and Hetero‐Subtypic Influenza ProtectionSmall, 2018
- Polysaccharide‐Based Controlled Release Systems for Therapeutics Delivery and Tissue Engineering: From Bench to BedsideAdvanced Science, 2018
- Biodegradable Polymeric Microparticles as Drug Delivery Devices2015
- Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccineMedical Microbiology and Immunology, 2009
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- Current Controversies in VaccinationJAMA, 2002
- Increased Incorporation of Chimeric Human Immunodeficiency Virus Type 1 gp120 Proteins into Pr55gagVirus-like Particles by an Epstein–Barr Virus gp220/350-Derived Transmembrane DomainVirology, 1997